Lpath and Sapient Discovery’s Collaborative Study That Characterized Favorable Interactions of Lpath's Anti-S1P Therapeutic Antibody with Its Target, Successfully Completed
Humanized Sphingomab is the candidate selected by Lpath for clinical study as an agent to treat cancer and various ocular diseases.
Lpath is the first to generate therapeutic monoclonal antibodies against S1P, an important bioactive lipid involved in angiogenesis and the progression of cancer.
Humanized Sphingomab™ has been shown on relevant animal modelss to have superior performance and more thermo-stable over the mouse monoclonal antibody. In addition, it has 20 times the binding affinity for its target than Genentech’s Avastin®.
Find more details from the press release.
Comment Preview